Two studies found a potential therapeutic role for vitamin C in thyroid cancer patients with BRAF V600 E mutation as vitamin C has antitumour effects and can kill cancer cells by MAPK/ERK and PI3K/AKT pathways. Here, AKT1 is linked to thyroid gland carcinoma.